OA13341A - Live genetically attenuated malaria vaccine. - Google Patents

Live genetically attenuated malaria vaccine. Download PDF

Info

Publication number
OA13341A
OA13341A OA1200600198A OA1200600198A OA13341A OA 13341 A OA13341 A OA 13341A OA 1200600198 A OA1200600198 A OA 1200600198A OA 1200600198 A OA1200600198 A OA 1200600198A OA 13341 A OA13341 A OA 13341A
Authority
OA
OAPI
Prior art keywords
plasmodium
dna
stage
sporozoites
berghei
Prior art date
Application number
OA1200600198A
Other languages
English (en)
Inventor
Stefan H I Kappe
Kai-Uwe C Matuschewski
Ann-Kristin Mueller
Original Assignee
Seattle Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Biomedical Res Inst filed Critical Seattle Biomedical Res Inst
Publication of OA13341A publication Critical patent/OA13341A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
OA1200600198A 2003-12-19 2004-12-20 Live genetically attenuated malaria vaccine. OA13341A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53147903P 2003-12-19 2003-12-19
US63122804P 2004-11-26 2004-11-26

Publications (1)

Publication Number Publication Date
OA13341A true OA13341A (en) 2007-04-13

Family

ID=34742995

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200600198A OA13341A (en) 2003-12-19 2004-12-20 Live genetically attenuated malaria vaccine.

Country Status (10)

Country Link
US (3) US7718165B2 (de)
EP (1) EP1706418B1 (de)
JP (1) JP2007515170A (de)
KR (1) KR20060123346A (de)
AU (1) AU2004309380B2 (de)
BR (1) BRPI0417762A8 (de)
CA (1) CA2551193C (de)
OA (1) OA13341A (de)
SG (1) SG149058A1 (de)
WO (1) WO2005063991A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087021A1 (en) * 1997-08-20 2007-04-19 Eng-Hong Lee Method of protecting against chronic infections
US8802919B2 (en) * 2002-04-05 2014-08-12 Sanaria Inc. Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production
US7718165B2 (en) * 2003-12-19 2010-05-18 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
US8168166B2 (en) * 2003-12-19 2012-05-01 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
US20050206225A1 (en) * 2004-03-18 2005-09-22 Ford Global Technologies, Llc Method and apparatus for predicting the position of a trailer relative to a vehicle
AP2008004448A0 (en) 2005-09-30 2008-04-30 Seattle Biomedical Res Inst Plasmodium liver stage antigens
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
AU2008202114B2 (en) * 2008-05-13 2011-08-25 Ruprecht-Karls-Universitat Heidelberg Live genetically attenuated malaria vaccine
EP2163627A1 (de) * 2008-09-12 2010-03-17 Bernhard-Nocht-Institut für Tropenmedizin Abgeschwächtes Leberstufen-Plasmodium und Impfstoff damit
CN102292103B (zh) 2009-01-16 2014-04-02 萨那里亚有限公司 纯化疟原虫(plasmodium)和疫苗组合物
US20110010782A1 (en) * 2009-07-09 2011-01-13 Microsoft Corporation Adapting parasites to combat disease
US20120288525A1 (en) 2011-05-11 2012-11-15 Chakravarty Sumana Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants
BR112014025823A8 (pt) * 2012-04-17 2017-07-25 Inst De Medicina Molecular Parasitas plasmodium de roedores utilizados como plataformas para uma vacina contra a malária á base de organismos inteiros
WO2014116990A1 (en) 2013-01-25 2014-07-31 Sanaria Inc. Genetic attenuation of plasmodium by b9 gene disruption
WO2015132338A1 (en) * 2014-03-06 2015-09-11 Stichting Katholieke Universiteit A genetically attenuated, live organism of the plasmodium genus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681762A (en) 1979-05-23 1987-07-21 Research Corporation Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
CA2171562A1 (en) * 1993-09-10 1995-03-16 Carla Cerami Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
DK0841392T3 (da) 1996-11-12 2004-11-22 Pfizer Svækket levende Neospora vaccine
ATE316139T1 (de) 1998-07-31 2006-02-15 Akzo Nobel Nv Attenuierte pferdeherpesvirus
CA2498604A1 (en) 2002-09-20 2004-04-01 Akzo Nobel N.V. Live antenuated parasite vaccine
CN1934448B (zh) 2002-11-20 2012-01-11 萨那里亚有限公司 疟疾预防方法
US7718165B2 (en) * 2003-12-19 2010-05-18 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine

Also Published As

Publication number Publication date
EP1706418B1 (de) 2018-08-22
US7261884B2 (en) 2007-08-28
US7122179B2 (en) 2006-10-17
US20080032388A1 (en) 2008-02-07
US7718165B2 (en) 2010-05-18
BRPI0417762A8 (pt) 2015-12-22
SG149058A1 (en) 2009-01-29
WO2005063991A2 (en) 2005-07-14
CA2551193A1 (en) 2005-07-14
AU2004309380A1 (en) 2005-07-14
AU2004309380B2 (en) 2010-04-29
EP1706418A2 (de) 2006-10-04
KR20060123346A (ko) 2006-12-01
BRPI0417762A (pt) 2007-04-17
US20050226896A1 (en) 2005-10-13
JP2007515170A (ja) 2007-06-14
WO2005063991A3 (en) 2005-09-09
US20070009556A1 (en) 2007-01-11
CA2551193C (en) 2011-02-01

Similar Documents

Publication Publication Date Title
Aly et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection
US7718165B2 (en) Live genetically attenuated malaria vaccine
Mueller et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine
Simwela et al. Current status of experimental models for the study of malaria
Mueller et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite–host interface
Goh et al. Vaccination with sporozoites: models and correlates of protection
Vaughan et al. Genetically engineered, attenuated whole-cell vaccine approaches for malaria
Mikolajczak et al. Disruption of the Plasmodium falciparum liver‐stage antigen‐1 locus causes a differentiation defect in late liver‐stage parasites
Pasini et al. Plasmodium knowlesi: a relevant, versatile experimental malaria model
US9764016B2 (en) Genetic attenuation of Plasmodium by B9 gene disruption
Solana et al. Live attenuated vaccines, a favorable strategy to provide long-term immunity against protozoan diseases
Sinnis et al. Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein
US7550138B1 (en) Plasmodium mutant and vaccines including the mutant
US20100210004A1 (en) Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
US8168166B2 (en) Live genetically attenuated malaria vaccine
US7722860B2 (en) Live genetically engineered protozoan vaccine
AU2008202114B2 (en) Live genetically attenuated malaria vaccine
AU2013250814B2 (en) Rodent Plasmodium parasites as platforms for a whole-organism malaria vaccine
Rôla Comparative efficacy analysis of whole-sporozoite vaccines against Malaria
Voss Advances in Malaria Malaria Transmission: From the Mosquito Midgut to the Mammalian Liver DAY 1–Wednesday, April 24, 2013
CN104736710A (zh) 来自恶性疟原虫的p47(pfs47)或来自间日疟原虫的p47(pvs47)作为疫苗或药物筛选靶标用于抑制人疟疾传播的用途
Romero Characterization of the Plasmodium MB2 gene family and evaluation of animal model systems for studying MB2 function
Othman et al. GENERATION AND ANALYSIS OF GENETICALLY ATTENUATED RODENT MALARIA PARASITES THAT ARREST LATE DURING LIVER STAGE DEVELOPMENT
de Andrade Characterization of a New Genetically Modified Plasmodium Berghei Parasite–Development of a Pre-Erythrocyte Malaria Vaccine
Zanghi Epigenetic studies of plasmodium falciparum pre-erythrocytic stages